› Forums › General Melanoma Community › Dr. Daud reviews ASCO 2016 immunology updates
- This topic has 12 replies, 3 voices, and was last updated 9 years, 6 months ago by
Bubbles.
- Post
-
- September 8, 2016 at 2:07 pm
I put up a post that covers Dr. Daud's review of ASCO 2016 immunology updates. The source is a prIME Oncology CME offering. I included a link in my post and I think you should be able to log-in on the site to see it for yourself. However, I put up a few of the slides and basic points on my post in case you cannot. If you are interested: http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2016/09/dr-daud-reviews-asco-2016-immunology.html
Wishing each of you well. Celeste
- Replies
-
-
- September 8, 2016 at 5:31 pm
Thanks Celeste for this posting. I was drawn to the Masterkey 265 study of T-Vec combined with PD-1. I'm on the Nivo long-term now, and my specialist has suggested concurrent T-Vec. Wow, the numbers look really promising. I am surprised T-Vec is not discussed more on this board, especially since it's an FDA approved treatment. I now anxiously await results of my tumor biopsy to at least know if I qualify. Getting the treatment, because of where I live is another matter altogether though.
Gary
-
- September 8, 2016 at 5:31 pm
Thanks Celeste for this posting. I was drawn to the Masterkey 265 study of T-Vec combined with PD-1. I'm on the Nivo long-term now, and my specialist has suggested concurrent T-Vec. Wow, the numbers look really promising. I am surprised T-Vec is not discussed more on this board, especially since it's an FDA approved treatment. I now anxiously await results of my tumor biopsy to at least know if I qualify. Getting the treatment, because of where I live is another matter altogether though.
Gary
-
- September 8, 2016 at 5:31 pm
Thanks Celeste for this posting. I was drawn to the Masterkey 265 study of T-Vec combined with PD-1. I'm on the Nivo long-term now, and my specialist has suggested concurrent T-Vec. Wow, the numbers look really promising. I am surprised T-Vec is not discussed more on this board, especially since it's an FDA approved treatment. I now anxiously await results of my tumor biopsy to at least know if I qualify. Getting the treatment, because of where I live is another matter altogether though.
Gary
-
- September 8, 2016 at 8:03 pm
Thanks Celeste. I had not seen this stat before for ipi/nivo:
- BRAF mutant (BRAF positive) patients had a 67% ORR to the combo. (NOTE: Previously BRAF status had not been a proven factor in response rate.)
-
- September 8, 2016 at 8:27 pm
I know, Mat. At one point years ago, there was some data saying that BRAF status DID affect response rates to immunotherapy. Then the pendulum shifted as data pointed to no affect on outcomes. Now this is out. So….not quite sure what the end result will be… Hope they'll figure out how to get good results, quickly…for everyone!!! C
-
- September 8, 2016 at 8:27 pm
I know, Mat. At one point years ago, there was some data saying that BRAF status DID affect response rates to immunotherapy. Then the pendulum shifted as data pointed to no affect on outcomes. Now this is out. So….not quite sure what the end result will be… Hope they'll figure out how to get good results, quickly…for everyone!!! C
-
- September 8, 2016 at 8:27 pm
I know, Mat. At one point years ago, there was some data saying that BRAF status DID affect response rates to immunotherapy. Then the pendulum shifted as data pointed to no affect on outcomes. Now this is out. So….not quite sure what the end result will be… Hope they'll figure out how to get good results, quickly…for everyone!!! C
-
- You must be logged in to reply to this topic.